Key Takeaways
- Hims & Hers Health, Inc. ($HIMS) reported fourth-quarter revenue of $245.8 million, missing analyst consensus estimates of $252.1 million.
- Shares of $HIMS plunged 18.5% to $10.15 in pre-market trading following the earnings announcement.
- The company's revised full-year 2024 revenue guidance was lowered to $1.01 billion - $1.03 billion, down from its previous forecast of $1.05 billion - $1.08 billion.
- This shortfall raises concerns among investors about the immediate impact of the company's strategic pivot towards higher-value service offerings.
Hims & Hers Navigates Strategic Pivot Amid Revenue Shortfall
Hims & Hers Health, Inc. ($HIMS) reported fourth-quarter revenue of $245.8 million, falling short of analyst expectations of $252.1 million, as the company attributed the miss to a deliberate strategic shift towards higher-value, personalized subscription services. This marks a significant deviation from its previous growth trajectory, which focused on broader customer acquisition at potentially lower average revenue per user. The company also reported adjusted earnings per share (EPS) of $0.11, narrowly missing the consensus estimate of $0.12.
The announcement triggered an immediate sell-off, with $HIMS shares plummeting 18.5% to $10.15 in pre-market trading, wiping out a substantial portion of its year-to-date gains. Volume surged to 3.5 million shares within the first hour of pre-market trading, far exceeding its average daily volume of 1.2 million shares, indicating significant investor reaction to the revised outlook and strategic implications.
Market Impact
$HIMS shares opened at $10.15, down from yesterday's close of $12.45, reflecting an 18.5% decline. This erased approximately $450 million from its market capitalization, bringing it to $2.1 billion. The stock's intraday low of $9.80 represents its lowest point since November 15, when it traded at $9.75, highlighting a rapid erosion of recent investor confidence.
This single-day percentage drop is the largest for $HIMS since its Q2 2022 earnings report, when shares fell 22% on August 8, 2022, following a broader market downturn impacting growth stocks. The increased trading volume, reaching 3.5 million shares in the first hour, suggests significant institutional rebalancing and a wave of retail profit-taking.
The negative sentiment around $HIMS could potentially weigh on other telehealth and direct-to-consumer health stocks, such as Teladoc Health ($TDOC) and GoodRx Holdings ($GDRX), which saw modest declines of 1.5% and 0.8% respectively in early trading. Investors may be reassessing the growth prospects and execution risks within the broader digital health sector, especially for companies undergoing strategic transformations.
What Analysts Are Saying
Goldman Sachs analysts, led by Sarah Smith, downgraded $HIMS to 'Neutral' from 'Buy,' lowering their 12-month price target to $11 from $15. "While the strategic pivot towards higher-margin services is logical long-term, the immediate revenue impact and lack of clear guidance on its ramp-up pose near-term execution risks," they noted in their client report. The firm highlighted that the slower growth in subscriber additions, which reached 1.7 million in Q4 compared to 1.65 million in Q3, was more pronounced than anticipated due to the shift.
Conversely, Piper Sandler maintained an 'Overweight' rating but adjusted their price target from $16 to $13. Analyst Thomas Lee stated, "The strategic shift is a necessary evolution for sustainable profitability and improved customer lifetime value. We believe the market is overreacting to the near-term revenue miss, overlooking the potential for improved gross margins, which expanded to 81% in Q4 from 79% year-over-year, and a stronger foundation for future profitability."
Jefferies analysts expressed concern over the company's revised full-year 2024 revenue guidance, which was lowered to $1.01 billion - $1.03 billion from the previous $1.05 billion - $1.08 billion. "This downward revision, coupled with the Q4 miss and a projected Q1 2025 revenue range of $255 million-$260 million (below consensus of $268 million), suggests a more challenging and prolonged transition than initially anticipated for Hims & Hers," they wrote in a client note, emphasizing the need for clearer milestones from management.
What to Watch
Investors will closely monitor $HIMS's Q1 2025 earnings call, specifically looking for updates on the traction of its new higher-value service offerings and any further revisions to its full-year guidance, which is expected around late April. The company's ability to demonstrate sequential growth in its premium subscription tiers and improved average revenue per user (ARPU) will be critical to rebuilding investor confidence.
Key technical support levels for $HIMS shares are identified at $9.70, which represents a previous consolidation point in late 2023, and then $8.50, corresponding to the 200-day moving average. A sustained break below these levels, particularly on high volume, could signal further downside pressure and a re-evaluation of its long-term growth narrative. Conversely, a rebound above $11.50 could indicate a stabilization of sentiment.
Competition in the telehealth and personalized health sector remains intense, with new entrants and established players continually expanding their services. Any significant competitive moves, such as new product launches or aggressive pricing from rivals like Ro or Optum, or regulatory changes impacting telemedicine could further complicate $HIMS's strategic pivot and market positioning.
The success of the "strategic shift" hinges on customer retention and the ability to effectively upsell existing users to premium services, rather than solely relying on new user acquisition. A failure to demonstrate improved customer lifetime value (CLTV) metrics and sustained gross margin expansion in upcoming reports could erode investor confidence, especially given the current revenue deceleration.
